The current financial score of PTC Therapeutics Inc is 7.49. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 357.81M, representing a year-over-year increase of 69.57%, while its net profit experienced a year-over-year increase of 425.20%.
The current valuation score of PTC Therapeutics Inc is 9.60. Its current P/E ratio is -27.11, which is -133.33% below the recent high of 9.04 and -29.84% above the recent low of -35.20.
The current earnings forecast score of PTC Therapeutics Inc is 8.40. The average price target is 101.07, with a high of 137.00 and a low of 62.00.
The current price momentum score of PTC Therapeutics Inc is 5.13. Currently, the stock price is trading between the resistance level at 72.85 and the support level at 61.94, making it suitable for range-bound swing trading.
The current institutional shareholding score of PTC Therapeutics Inc is 10.00. The latest institutional shareholding proportion is 125.84%, representing a quarter-over-quarter increase of 17.66%.
The current risk assessment score of PTC Therapeutics Inc is 6.89. The company's beta value is 0.54. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.